🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst

Published 17/06/2024, 17:15
© Reuters.  Legend Biotech\'s Cancer Drug, \'The Most Attractive Product,\' Set For Growth: Analyst

Benzinga - by Priya Nigam, Benzinga Staff Writer.

Shares of cell therapy company Legend Biotech Corp (NASDAQ:LEGN) were trading lower on Monday, after being among the top pharma gainers in the first week of June.

The company's Carvykti drug is likely to return to growth and revive investor enthusiasm, according to Truist Securities.

The Legend Biotech Analyst: Asthika Goonewardene initiated coverage of Legend Biotech with a Buy rating and price target of $88.

The Legend Biotech Thesis: In a landmark collaboration with Johnson & Johnson (NYSE:JNJ), the company launched Carvykti, which is "the most attractive product" for treating multiple myeloma, Goonewardene said in the initiation note.

Check out other analyst stock ratings.

"Our spot survey of CAR-T prescribers indicate intentions to increase Carvykti use at a run-rate that is more than double that of last year," the analyst wrote. Carvykti could generate more than 96% year-on-year growth in sales, "and as a revenue generating biotech, we think this will more favorably impact sentiment on LEGN over binary clinical developments," he added.

Cell therapies in Multiple Myeloma are estimated to be worth more than $15 billion in the major Western markets and Carvykti can be an over $5 billion product, Goonewardene further said.

LEGN Price Action: Shares of Legend Biotech were down 2.5% to $41.38 at the time of publication on Monday.

Now Read: EXCLUSIVE: What Matters Most To Retail Investors At GameStop’s Annual Shareholders Meeting – Roaring Kitty, Crypto, Or Turnaround?

Image generated using artificial intelligence via Midjourney.

Latest Ratings for LEGN

Mar 2022Morgan StanleyMaintainsOverweight
Jan 2022Morgan StanleyUpgradesEqual-WeightOverweight
Jan 2022Morgan StanleyDowngradesOverweightEqual-Weight
View More Analyst Ratings for LEGN

View the Latest Analyst Ratings

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.